U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,837.70
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.1819%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.1088%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.2696%)
     
  • BTC-USD

    19,081.33
    +33.04 (+0.17%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

What's in Store for Fidelity National's (FIS) Q1 Earnings?

Zacks Equity Research
·3 min read

Fidelity National Information Services FIS is scheduled to release first-quarter 2020 earnings on May 7, before the bell. The company’s sales are anticipated to reflect year-over-year growth, while earnings might display a decline.

Notably, Fidelity delivered positive earnings surprises in three of the trailing four quarters and in-line numbers in the other, the average positive beat being 3.09%.

In the last reported quarter, the company’s results surpassed the Zacks Consensus Estimate. Organic revenue growth and expanding margin were key tailwinds. However, significant rise in expenses posed a key concern.
 

Fidelity National Information Services, Inc. Price and EPS Surprise

Fidelity National Information Services, Inc. Price and EPS Surprise
Fidelity National Information Services, Inc. Price and EPS Surprise

Fidelity National Information Services, Inc. price-eps-surprise | Fidelity National Information Services, Inc. Quote

Factors at Play

Fidelity is likely to display a strong revenue-growth performance for the January-March quarter as underlying business trends remained robust. Notably, overall revenues of $3.1 billion are projected to surge 49.7% from the prior-year quarter.

This Florida-based financial service provider’s bottom-line results might disappoint on fall in interest rates due to the coronavirus mayhem.

The company’s focus on rolling out innovative products in order to meet customers’ rising demand might have inflated expenses.

Fidelity’s shares have lost 12.5% in the three-month period ended Mar 31, 2020, compared with the industry’s decline of 18.3%.

Will the upcoming earnings release give a boost to Fidelity’s stock? That depends largely on whether or not the firm is able to impress the market with its first-quarter results.

Here is what our quantitative model predicts:

Fidelity does not have the right combination of the two key ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or higher — for increasing the odds of an earnings beat.

You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: The Earnings ESP is currently pegged at 0.00%.

Zacks Rank: It currently carries a Zacks Rank of 3.

Notably, the Zacks Consensus Estimate for the first-quarter earnings suggests a 22.6% decline on a year-over-year basis.

Stocks That Warrant a Look

Eagle Bancorp Montana, Inc. EBMT has been witnessing upward estimate revisions, for the past 30 days. Moreover, this Zacks #2 Ranked (Buy) stock has lost more than 9%, in the past six months. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GAIN Capital Holdings, Inc. GCAP has been recording upward estimate revisions, for the past 30 days. Also, the company’s shares have gained 43.6% in six months’ time. At present, it flaunts a Zacks Rank of 1.

Tradeweb Markets Inc. TW has been witnessing upward estimate revisions for the past 30 days. Additionally, the stock has rallied 32.3% over the past six months. It currently sports a Zacks Rank #1.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Fidelity National Information Services, Inc. (FIS) : Free Stock Analysis Report
 
Tradeweb Markets Inc. (TW) : Free Stock Analysis Report
 
Eagle Bancorp Montana, Inc. (EBMT) : Free Stock Analysis Report
 
GAIN Capital Holdings, Inc. (GCAP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research